Navigation Links
Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C
Date:4/25/2009

cause serious liver disease, leading to cirrhosis, primary liver cancer and even death. Patients infected with the genotype 1 hepatitis C virus account for approximately 75% of the chronic hepatitis C patients in the U.S.

About Human Genome Sciences

The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs. The HGS clinical development pipeline includes novel drugs to treat hepatitis C, lupus, inhalation anthrax and cancer.

The Company's primary focus is rapid progress toward the commercialization of its two lead drugs, Albuferon(R) (albinterferon alfa-2b) for hepatitis C and LymphoStat-B(R) (belimumab) for lupus. The filing of global marketing applications for Albuferon is planned in fall 2009. Two Phase 3 clinical trials of LymphoStat-B are ongoing, with results expected in July and November 2009.

In January 2009, HGS began delivery of 20,000 doses of ABthrax(TM) (raxibacumab) to the U.S. Strategic National Stockpile for use in the event of an emergency for the treatment of inhalation anthrax; completion of delivery is expected in the second quarter. The Company also has several drugs in earlier stages of clinical development for the treatment of cancer, led by the TRAIL receptor antibody HGS-ETR1 and a small-molecule antagonist of IAP (inhibitor of apoptosis) proteins. In addition, HGS has substantial financial rights to certain products in the GSK clinical pipeline including darapladib, currently in Phase 3 development as a potential treatment for coronary heart disease, and Syncria(R) (albiglutide), currently in Phase 3 development as a potential treatment for type 2 diabetes.

For more information about HGS, please visit the Company's web site at www.hgsi.com. To view the EASL oral presentation reporting results of the ACHIEVE 1 clinical t
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Data Presented at AACR Annual Meeting Show Anti-Tumor Activity of Peregrines Fully Human Anti-PS Antibody in Prostate Cancer Model
2. Micromet Presents Preclinical Data Showing Activity of Erbitux and Vectibix Based BiTE Antibodies against KRAS- and BRAF-mutated Human Colorectal Cancer Cells
3. Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)
4. First Human Study to Show Sun Chlorella A Supports Heart Health
5. Nobilon Advances First Vaccine Into Human Trials - Intranasal Influenza Vaccine Begins Phase I Clinical Development
6. Alimera Reports Favorable Safety and Efficacy Results From the 12-Month Interim Readout of the Human PK Iluvien(TM) Study
7. Neuralstems Human Stem Cells Integrate into Nervous System of Rats with Animal Model of ALS
8. Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C
9. Drug Development Program Started Based on CAP(R) Human Cell Line
10. Human Genome Sciences Announces Fourth-Quarter and Full-Year 2008 Financial Results and Key Developments
11. IlluminOss Medical Announces First Human Case Utilizing a Unique, New, Minimally Invasive Technology for Fracture Repair is Performed at Medical Hospital del Trabajadar in Santiago, Chile
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014 The consumer marketing playbook and ... sectors to better identify winning tools and techniques. ... with and understand consumers, as new technologies are ... purchasing decisions. According to recent ... area where organizations can observe a deep pool ...
(Date:7/11/2014)... 2014  Kindred Hospital Houston Northwest, with Wound ... of its new outpatient wound healing center.  The ... with chronic, hard to heal wounds. Chronic wounds ... amputation, lower leg wounds related to blood flow ... traumatic injury wounds which are complex and demonstrate ...
(Date:7/11/2014)... July 11, 2014  Veran Medical Technologies, ... today the positive, cost-effective final results for ... procedure. The SPiNPerc endobronchial percutaneous biopsy study ... approach to biopsy when a traditional bronchoscopic ... physicians experience positive financial outcomes when more ...
Breaking Medicine Technology:New Technologies Transforming Consumer Marketing Research Playbook 2Kindred Hospital Houston Northwest, With Wound Care Specialists, Opens Outpatient Wound Healing And Hyperbaric Center 2Veran Medical Publishes Lung Cancer Patient Management Study 2
... Scientific Presentations Detail Progress with VeraTag(TM) Assays in Breast ... ... (Nasdaq: MGRM ) today announced five posters to be,presented at the 30th ... - 16, 2007. Following are details for,each embargoed session:, -- Friday, ...
... Tainted Research Grant Applications Must Be Rejected, Consumer,Advocates ... More apparent,conflict of interest violations in applications for ... were revealed today and the,Foundation for Taxpayer and ... to be rejected., The latest improprieties were ...
Cached Medicine Technology:Monogram Announces Posters to be Presented at the 30th San Antonio Breast Cancer Symposium 2Monogram Announces Posters to be Presented at the 30th San Antonio Breast Cancer Symposium 3New Conflict of Interest Violations Revealed at California Stem Cell Institute 2New Conflict of Interest Violations Revealed at California Stem Cell Institute 3
(Date:7/13/2014)... 13, 2014 Intraocular Lens (IOL) Market: ... 2013 - 2019 , Intraocular lens (IOL) is inserted ... or cataracts. The lenses are inserted inside the eye, ... intraocular lens replaces the focusing power of natural lens. ... lens to deliver the light focusing function which was ...
(Date:7/13/2014)... 13, 2014 Victorian Hotel has recently ... the rental of bikes for its "Cycle the City" ... Hotel to tour the area using a rental bicycle, ... enthusiasts love to call Vancouver home, as it is ... travel and picturesque journeys through the countryside. Vancouver hotel ...
(Date:7/13/2014)... additives are chemicals, which are added to various fuels ... on, in order to enhance their performance. Fuel additives ... by fuels and improving the combustion properties of fuels. ... scale in the long run, but, in the short ... products. , The various fuel additive types include deposit ...
(Date:7/13/2014)... Houston, TX (PRWEB) July 13, 2014 The ... for children ranging in age from four months to 12 ... skills and karate classes to birthday parties and Summer Camps, ... the Little Gym of Pearland after spending over ... variety of roles, including Gym Director. , Berry has ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 Recently, MyDressCity.com, ... and women’s special occasion outfits, has released its new ... all the new products are available at discounted prices. ... 26, 2014. , In the company’s online shop, ... all of them are made with great materials. MyDressCity.com’s ...
Breaking Medicine News(10 mins):Health News:Intraocular Lens (IOL) Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 2Health News:Intraocular Lens (IOL) Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 3Health News:Intraocular Lens (IOL) Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 4Health News:Victorian Hotel Creates Excitement by Adding "Cycle the City" Bike Rentals for Its Vancouver Hotel Rooms 2Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 2Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 3Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 4Health News:The Little Gym of Pearland, TX Now Under New Ownership and Management 2Health News:Cheap Elegant Quinceanera Dresses Unveiled by MyDressCity.com 2
... , RANCHO CORDOVA, Calif., Dec. 10 ThermoGenesis Corp. ... for processing and storing adult stem cells, said today that ... healthcare industry experience, has been named to the Company,s board ... directors to six. , Moore is currently associated with several ...
... , , EXTON, Pa., Dec. 10 Kensey Nash ... directors has approved a stock repurchase. The new program allows ... its issued and outstanding shares of Common Stock and has no ... its available cash. , Kensey Nash Corporation plans to repurchase its ...
... an early sign of Parkinson,s disease, according to neurologists ... to slow further brain cell damage until strategies to ... an age-related disorder involving loss of certain types of ... speech. "The disease is currently diagnosed by ...
... ... and challenges of leveraging communications technologies before, during and after crises , ... Washington, DC and London, ... released a landmark publication today, Human Rights Day, on the use of communications ...
... ST. LOUIS, Dec. 10 Centene Corporation (NYSE: ... 2010 financial guidance at approximately 6:00 AM (Eastern Time) on ... at approximately 8:30 AM (Eastern Time) to discuss the details ... Officer, and William N. Scheffel, Executive Vice President, Chief Financial ...
... PARK CITY, Utah, Dec. 10 Nutraceutical International Corporation (Nasdaq: ... and year ended September 30, 2009. Net sales for the ... for the same quarter of fiscal 2008. For the fourth ... diluted earnings per share, compared to net income of $1.5 million, ...
Cached Medicine News:Health News:ThermoGenesis Corp. Names Healthcare Industry Executive Craig Moore to Board of Directors 2Health News:ThermoGenesis Corp. Names Healthcare Industry Executive Craig Moore to Board of Directors 3Health News:ThermoGenesis Corp. Names Healthcare Industry Executive Craig Moore to Board of Directors 4Health News:Kensey Nash Announces 400,000 Share Stock Repurchase Program 2Health News:Kensey Nash Announces 400,000 Share Stock Repurchase Program 3Health News:Irregular arm swing may point to Parkinson's disease 2Health News:New Report Examines the Role of Communications Technologies in Humanitarian Crises, 2Health News:New Report Examines the Role of Communications Technologies in Humanitarian Crises, 3Health News:New Report Examines the Role of Communications Technologies in Humanitarian Crises, 4Health News:Centene Corporation to Provide 2010 Financial Guidance On January 8, 2010 2Health News:Centene Corporation to Provide 2010 Financial Guidance On January 8, 2010 3Health News:Nutraceutical Reports Fiscal 2009 Year End Results 2Health News:Nutraceutical Reports Fiscal 2009 Year End Results 3Health News:Nutraceutical Reports Fiscal 2009 Year End Results 4Health News:Nutraceutical Reports Fiscal 2009 Year End Results 5Health News:Nutraceutical Reports Fiscal 2009 Year End Results 6Health News:Nutraceutical Reports Fiscal 2009 Year End Results 7Health News:Nutraceutical Reports Fiscal 2009 Year End Results 8
Pipetman P is a fully adjustable, air-displacement pipette with the selected volume shown on a digital indicator (volumeter). Eight models cover the full range of volumes from 0.2 L to 10 mL....
... Finnpipette Digital offers improved ergonomics for ... handle, modified grippy finger rest and ... comfort and efficiency. Finnpipette Digitals also ... gearing mechanism (pat. pend.) and super ...
Research Series 2100 Adjustable-volume Pipette,100-1,000 l, single-channel with adjustable-volume setting...
... The Sysmex pocH-100i is the first ... with low daily testing requirements. With its ... 3-part differential from just 15 L of ... for any small healthcare site including the ...
Medicine Products: